Month: February 2024

MALVERN, Pa., Feb. 28, 2024 (GLOBE NEWSWIRE) — Vishay Precision Group, Inc. (NYSE: VPG), a leader in precision measurement and sensing technologies, announced that the company will present at the Sidoti March 2024 Small-Cap Virtual Investor Conference on Thursday, March 14, 2024 at 10:45 a.m. ET. A live and on-demand webcast of VPG’s presentation will be available to the public and can be accessed from the following link: https://sidoti.zoom.us/webinar/VPG, or on VPG’s website: ir.vpgsensors.com/events. For more information, or for help arranging a one-on-one meeting at the conference, please contact: info@vpgsensors.com. About VPG Vishay Precision Group, Inc. (VPG) is a leader in precision measurement and sensing technologies. Our sensors, weighing solutions and measurement systems optimize and enhance our customers’ product...

JUPITER, Fla. and BUNNIK, the Netherlands, Feb. 28, 2024 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on applying its innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health today announced its Dutch subsidiary, Dyadic Nederland BV has entered into a strategic partnership agreement and collaboration with Rabian BV (“Rabian”), a Dutch innovative SME founded by experienced entrepreneurs and vaccine scientists. The aim is to develop highly efficacious, scalable, and affordable rabies prophylactics and vaccines utilizing Dyadic’s C1 protein production...

ROSELAND, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announces it has commenced direct sales of its STA Single Tooth Anesthesia System® (STA) with Meridian Endo & Perio, a large endodontics, periodontics and implant dentistry practice with three offices in Wisconsin. Dr. Lisa Teel, periodontist and implant surgeon with Meridian Endo and Perio, stated, “Our practice is committed to adopting the latest technologies to improve the overall patient experience. Upon introduction, we were struck by the ease of use, as well as the STA’s ability to put patients at ease with dental anesthesia. Notably, it was initially our endodontists using the STA. However, as patients were cross-referred...

VANCOUVER, British Columbia, Feb. 28, 2024 (GLOBE NEWSWIRE) — VERSES AI Inc. (CBOE: VERS) (OTCQB: VRSSF) (“VERSES” or the “Company”), a cognitive computing company specializing in the next generation of intelligent software systems, is pleased to announce that its CEO, Mr. Gabriel René will be conducting a webinar on Thursday, February 29th at 11:00am Eastern Standard Time. On this call, investors will have the opportunity to learn how AI (artificial intelligence) companies test and compare their latest AI products against each other and get a glimpse into the results that the VERSES team has achieved to date. Attendees of this webinar will learn about:How video games are used to evaluate AI systems Common AI benchmark tests used to evaluate all AI systems The importance of standard comparisons of AI approaches VERSES...

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its partnership with Cliantha Research, a full-service Clinical Research Organization (CRO), to perform a pharmacokinetic (PK) study forming part of the Company’s FDA 510(k) clinical study plan. The Company’s PK study will recruit 40 healthy adult subjects under an IRB/EC and regulatory approved protocol and compare the amounts of opiates in fingerprint sweat versus blood, oral fluid and urine specimens following the medically supervised administration of drugs. All fingerprint sweat, blood, oral fluid and urine specimens will be analyzed by a validated, traceable liquid chromatography...

The Company Plan for the Buy Back of Up to $200 Million of Shares Recently Commenced at Compelling Valuation Levels, Aiming to Improve Enterprise Value A Second Advanced 3D Printer for Electronics Was Sold to an Existing Customer – a Leading Western Defense Agency A Breakthrough in Materials – Nano Dimension Filed a Patent Application For INSU™ 200 – the Most Effective Additive Dielectric Material for Electronics Under Development for Years Waltham, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) — Nano Dimension Ltd. (Nasdaq: NNDM) (“Nano Dimension” or the “Company”), a leading supplier of Additively Manufactured Electronics (“AME”) and multi-dimensional polymer, metal & ceramic Additive Manufacturing (“AM”) 3D printing solutions, today announced a series of updates covering its repurchase plan, repeat customer success,...

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, March 6, 2024, to review the company’s fourth quarter and full year 2023 financial results and provide business updates. The webcast and conference call may be accessed by visiting “Investor Events” on the investors section of the Wave Life Sciences website: ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can join the conference call at the following audio conferencing link: available here. Once registered, participants will receive the dial-in information. Following...

All animal subjects tolerated maximum dosing Once-per-day human intranasal dosing regimen determined for clinical evaluation SARASOTA, FL, Feb. 28, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced positive results from its non-GLP small animal dose-ranging study of SPC-15, an intranasal prophylactic treatment for anxiety and post-traumatic stress disorder (PTSD). The purpose of the non-GLP small animal study was to identify the maximum tolerated intranasal dose of the drug pharmacokinetic and determine the therapeutically relevant dose range to be studied in clinical trials. Data analysis demonstrated rapid absorption...

TORONTO, Feb. 28, 2024 (GLOBE NEWSWIRE) — Colliers International Group Inc. (TSX and NASDAQ: CIGI) (“Colliers” or the “Company”) is pleased to report that it has closed its previously announced bought deal public offering of 2,479,500 subordinate voting shares (the “Subordinate Voting Shares”), at a price of US$121.00 per Subordinate Voting Share for gross proceeds of US$300.0 million (the “Offering”) with a syndicate of underwriters led by BMO Capital Markets and J.P. Morgan as joint bookrunners, and including Mizuho, National Bank Financial, RBC Capital Markets, Scotiabank, Merrill Lynch, BTIG, LLC, CIBC Capital Markets, Goldman Sachs, Raymond James, TD Securities, Wells Fargo and Stifel Nicolaus (the “Underwriters”). Colliers has granted the Underwriters an option, exercisable at the offering price for a period of 30 days following...